MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating ...

Stream 'Visual Disturbances (2019)' and watch online. Discover streaming options, rental services, and purchase links for this movie on Moviefone. Watch at home and immerse yourself in this movie's ...

Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating ...

RESEARCH TRIANGLE PARK, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases ...

PITTSBURGH, June 2, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from LYNX-2, a pivotal Phase 3 trial evaluating MR-142 ...

A study led by Jonathan Michaels, a Faculty of Health professor at York's School of Kinesiology and Health Science, reveals ...